All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): KPG-818
Therapeutic Area: Immunology Product Name: KPG-818
Highest Development Status: Phase I/ Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2020
Details:
The Phase Ib/IIa multicenter, randomized, double-blind, placebo-controlled clinical study will evaluate the safety and tolerability, pharmacokinetics and preliminary efficacy of KPG-818 in patients with mild to moderate SLE.